



Focus on
Pancreatic
and GI –Based
Cancers

FrostBite™



GastroCS™



The CPSI Biotech **FrostBite™** and **GastroCS™** System provides for a next generation approach to treating **Pancreatic Cancer** and other **Gastroenterological based diseases**

Technology Overview

CPSI Biotech's **FrostBite™** cryoablation catheter is a flexible endoscopic ultrasound compatible disposable ablation cryoprobe technology which when utilized in combination with the **GastroCS™** PSN (Pressurized Sub-Cooled Nitrogen) cryoablation system offers a next generation technology platform for the treatment of pancreatic cancer and other gastrointestinal diseases including Pancreatic, Esophageal, Stomach and Colorectal Cancers as well as Barrett's Esophagus.

The **FrostBite™** cryocatheter is a dual lumen, flexible endoscopic compatible catheter enabling the application of multiple therapeutic and diagnostic approaches (pharmaceutical, dual-ablation, cell and gene therapy, among others) in a single device format. This technology platform enables advanced personalized treatment regimens for patients suffering from numerous gastrointestinal tissue diseases which are untreatable or inadequately treated with today's state of the art devices.

FrostBite™ Cryoablation Disposables

- Supports endoscopic based tumor access
- Flexible, Steerable needle tipped catheters
- Handle control operation and displays
- Compatibility with a variety of tip configurations
 - Needle, spot, linear, balloon, etc.
- *RapidRelease* thawing technology
- Ice formation within 15 seconds
- Tissue freeze completed within 5 minutes
- Minimal pain and shortened hospitalization


GastroCS™ PSN System

- Converts N2 Gas to Mixed Phase N2
- Self-contained device
- Dual Port supporting multi-probes if desired
- The PSN (*Pressurized Sub-Cooled Nitrogen*) System allows for:
 - Cryogen delivery via ultrafine tubing
 - Rapid heat extraction from tissue
 - Recycling of cryogen during operation
 - Continuous delivery of ultra-cold cryogen
- Delivers superior ablation capacity to Argon and other J-T Based Cryoablation Systems

Market Overview

The global market for treatment of GI based cancers is projected to reach \$2.5 billion in 2016. Forecast growth of ~18% annually reaching ~\$5 billion in 2020. The potential market for ablation devices (equipment and consumables) used for treatment of PaCa and other GI cancers was ~\$500 million in 2013. Based on an initial modest 10% market penetration 1yr post launch, CPSI anticipates generating annual revenues of ~\$10 MM from product sales after 3 years, ~\$25MM after 5 years and >\$50MM after 8 years from initial investment and product launch.

Evaluation of the ablation zone and thermal profile generated by the FrostBite™ in an *ex vivo*



pancreatic cancer tumor model. The PaCa TEM was utilized to assess the ablation zone created by the FrostBite™ cryocatheter in conjunction with the GastroCS™ PSN System and demonstrated the successful generation of a 2.5cm ablation zone following a 5 min ablation period. (Snyder, *et al.*, ACCryo2013)

Intellectual Property

Patents pending with the USPTO covering:

- ❖ Cryoablation system for minimally-invasive treatment of cancerous tissue
- ❖ Line of EUS compatible catheters for use with the PSN System
- ❖ Minimally invasive methodological approach for the cryoablative treatment of pancreatic based on ultrasound guided esophageal access trans-stomach based approach to access and ablate pancreatic tumors in situ.


COMPETITIVE ADVANTAGE

Performance Differentiator

- ❖ Speed, power and heat extraction capacity
- ❖ Only EUS (endoscopic ultrasound) compatible cryoprobe system
- ❖ Closed loop system

Cost Differentiator

- ❖ Elimination of costly argon and nitrous oxide
- ❖ Green technology – use of nitrogen
- ❖ Single console supporting multiple approaches
- ❖ Reduced procedure time, OR time, risk and cost



EUS Image of FrostBite™ testing in a porcine model. A) EUS image of the porcine stomach and pancreas; B) Image of the FrostBite™ probe extending out of the EUS accessory channel and in contact with the stomach wall; C) Image of the probe tip being extended into the target tissue; D) Image of the frozen tissue mass created by FrostBite™ after 4 minutes of freezing. (Kashab, *et al.* ACCryo2014)

Business Development and Investment Opportunity

Our mission is to rapidly translate new and innovative technologies through the concept and development phases and into the commercialization stage to bring these technologies to the market. In support of these efforts, CPSI Biotech welcomes inquires and discussions pertaining to equity investment as well as business relationships (sales, acquisition, licensing, or partnering) for the FrostBite™ and GastroCS™ System.

Caution: Investigational Devices Limited by Federal Law to Investigational Use Only